S Lailach1, T Schenke2, I Baumann3, H Walter3, M Praetorius3, T Beleites2, T Zahnert2, M Neudert2. 1. Klinik und Poliklinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf-Hals-Chirurgie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland. Susen.Lailach@uniklinikum-dresden.de. 2. Klinik und Poliklinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf-Hals-Chirurgie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland. 3. Hals-Nasen-Ohren-Klinik, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland.
Abstract
BACKGROUND: Otosclerosis affects health-related quality of life (HRQOL). Until now, measurements have only been performed using audiometric data or non-validated quality of life questionnaires. OBJECTIVE: The objective of this study was to develop the first validated disease-specific HRQOL measuring instrument to determine HRQOL in otosclerosis. MATERIALS AND METHODS: After sequential analysis and item reduction of the initial Stapesplasty Outcome Test 47 (SPOT-47), the SPOT-25 was validated prospectively on 52 otosclerosis patients undergoing stapes surgery. In addition to the overall score, four subscores were defined (hearing function, tinnitus, social restrictions, mental condition). RESULTS: The SPOT-25 showed a high internal consistency (Cronbach's α > 0.7), allowed discrimination between otosclerosis patients and healthy subjects, and demonstrated acceptable test-retest reliability (r = 0.85). After stapes surgery, the HRQOL improved significantly. The responsiveness was high. CONCLUSION: The SPOT-25 is the first validated disease-specific instrument for HRQOL measurement in otosclerosis patients. It should be used routinely for quality control.
BACKGROUND:Otosclerosis affects health-related quality of life (HRQOL). Until now, measurements have only been performed using audiometric data or non-validated quality of life questionnaires. OBJECTIVE: The objective of this study was to develop the first validated disease-specific HRQOL measuring instrument to determine HRQOL in otosclerosis. MATERIALS AND METHODS: After sequential analysis and item reduction of the initial Stapesplasty Outcome Test 47 (SPOT-47), the SPOT-25 was validated prospectively on 52 otosclerosispatients undergoing stapes surgery. In addition to the overall score, four subscores were defined (hearing function, tinnitus, social restrictions, mental condition). RESULTS: The SPOT-25 showed a high internal consistency (Cronbach's α > 0.7), allowed discrimination between otosclerosispatients and healthy subjects, and demonstrated acceptable test-retest reliability (r = 0.85). After stapes surgery, the HRQOL improved significantly. The responsiveness was high. CONCLUSION: The SPOT-25 is the first validated disease-specific instrument for HRQOL measurement in otosclerosispatients. It should be used routinely for quality control.
Authors: Alicia M Quesnel; Reuven Ishai; Sebahattin Cureoglu; Fred Linthicum; Ivan A Lopez; Joseph B Nadol; Michael J McKenna Journal: Otol Neurotol Date: 2016-04 Impact factor: 2.311
Authors: Digna M A Kamalski; Robert Vincent; Inge Wegner; Arnold J N Bittermann; Wilko Grolman Journal: Otol Neurotol Date: 2014-12 Impact factor: 2.311
Authors: Dan Bagger-Sjöbäck; Karin Strömbäck; Malou Hultcrantz; Georgios Papatziamos; Henrik Smeds; Niklas Danckwardt-Lillieström; Bo Tideholm; Ann Johansson; Sten Hellström; Pierre Hakizimana; Anders Fridberger Journal: Sci Rep Date: 2015-08-21 Impact factor: 4.379
Authors: Juha T Laakso; Juha Silvola; Timo Hirvonen; Samuli Suutarla; Ilkka Kivekäs; Riitta Saarinen; Lotta Haavisto; Jaakko Laitakari; Antti A Aarnisalo; Aarno Dietz; Jussi Jero; Maija Hytönen; Saku T Sinkkonen Journal: J Otol Date: 2021-01-20